747 related articles for article (PubMed ID: 32641760)
21. Control of Gut Inflammation by Modulation of Purinergic Signaling.
Vuerich M; Mukherjee S; Robson SC; Longhi MS
Front Immunol; 2020; 11():1882. PubMed ID: 33072065
[TBL] [Abstract][Full Text] [Related]
22. Targeting the CD73-adenosine axis in immuno-oncology.
Allard D; Chrobak P; Allard B; Messaoudi N; Stagg J
Immunol Lett; 2019 Jan; 205():31-39. PubMed ID: 29758241
[TBL] [Abstract][Full Text] [Related]
23. The adenosine generating enzymes CD39/CD73 control microglial processes ramification in the mouse brain.
Matyash M; Zabiegalov O; Wendt S; Matyash V; Kettenmann H
PLoS One; 2017; 12(4):e0175012. PubMed ID: 28376099
[TBL] [Abstract][Full Text] [Related]
24. Purinergic signaling in liver disease.
Vaughn BP; Robson SC; Longhi MS
Dig Dis; 2014; 32(5):516-24. PubMed ID: 25034284
[TBL] [Abstract][Full Text] [Related]
25. The role of adenosinergic pathway in human autoimmune diseases.
Dong K; Gao ZW; Zhang HZ
Immunol Res; 2016 Dec; 64(5-6):1133-1141. PubMed ID: 27665459
[TBL] [Abstract][Full Text] [Related]
26. Elevated CD39+T-Regulatory Cells and Reduced Levels of Adenosine Indicate a Role for Tolerogenic Signals in the Progression from Moderate to Severe COVID-19.
Elsaghir A; El-Sabaa EMW; Zahran AM; Mandour SA; Salama EH; Aboulfotuh S; El-Morshedy RM; Tocci S; Mandour AM; Ali WE; Abdel-Wahid L; Sayed IM; El-Mokhtar MA
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139439
[TBL] [Abstract][Full Text] [Related]
27. Adenosine and adenosine receptors in colorectal cancer.
Hajizadeh F; Masjedi A; Heydarzedeh Asl S; Karoon Kiani F; Peydaveisi M; Ghalamfarsa G; Jadidi-Niaragh F; Sevbitov A
Int Immunopharmacol; 2020 Oct; 87():106853. PubMed ID: 32755765
[TBL] [Abstract][Full Text] [Related]
28. Human follicular lymphoma CD39+-infiltrating T cells contribute to adenosine-mediated T cell hyporesponsiveness.
Hilchey SP; Kobie JJ; Cochran MR; Secor-Socha S; Wang JC; Hyrien O; Burack WR; Mosmann TR; Quataert SA; Bernstein SH
J Immunol; 2009 Nov; 183(10):6157-66. PubMed ID: 19864600
[TBL] [Abstract][Full Text] [Related]
29. Tinkering with targeting nucleotide signaling for control of intracellular Leishmania parasites.
Vijayamahantesh ; Vijayalaxmi
Cytokine; 2019 Jul; 119():129-143. PubMed ID: 30909149
[TBL] [Abstract][Full Text] [Related]
30. Purinergic signaling: a potential therapeutic target for ischemic stroke.
Wang L; Li YJ; Yang X; Yang B; Zhang X; Zhang J; Zhang Q; Cheng XD; Wang JH; Yu NW
Purinergic Signal; 2023 Mar; 19(1):173-183. PubMed ID: 36370253
[TBL] [Abstract][Full Text] [Related]
31. The CD39-adenosinergic axis in the pathogenesis of renal ischemia-reperfusion injury.
Roberts V; Lu B; Rajakumar S; Cowan PJ; Dwyer KM
Purinergic Signal; 2013 Jun; 9(2):135-43. PubMed ID: 23188420
[TBL] [Abstract][Full Text] [Related]
32. Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells.
Mandapathil M; Szczepanski MJ; Szajnik M; Ren J; Jackson EK; Johnson JT; Gorelik E; Lang S; Whiteside TL
J Biol Chem; 2010 Sep; 285(36):27571-80. PubMed ID: 20558731
[TBL] [Abstract][Full Text] [Related]
33. Adenosine signaling: Next checkpoint for gastric cancer immunotherapy?
Shi L; Yang L; Wu Z; Xu W; Song J; Guan W
Int Immunopharmacol; 2018 Oct; 63():58-65. PubMed ID: 30075429
[TBL] [Abstract][Full Text] [Related]
34. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression.
Deaglio S; Dwyer KM; Gao W; Friedman D; Usheva A; Erat A; Chen JF; Enjyoji K; Linden J; Oukka M; Kuchroo VK; Strom TB; Robson SC
J Exp Med; 2007 Jun; 204(6):1257-65. PubMed ID: 17502665
[TBL] [Abstract][Full Text] [Related]
35. Adenosine production by human B cells and B cell-mediated suppression of activated T cells.
Saze Z; Schuler PJ; Hong CS; Cheng D; Jackson EK; Whiteside TL
Blood; 2013 Jul; 122(1):9-18. PubMed ID: 23678003
[TBL] [Abstract][Full Text] [Related]
36. ATP and Its Metabolite Adenosine as Regulators of Dendritic Cell Activity.
Silva-Vilches C; Ring S; Mahnke K
Front Immunol; 2018; 9():2581. PubMed ID: 30473700
[TBL] [Abstract][Full Text] [Related]
37. CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death.
Serra S; Horenstein AL; Vaisitti T; Brusa D; Rossi D; Laurenti L; D'Arena G; Coscia M; Tripodo C; Inghirami G; Robson SC; Gaidano G; Malavasi F; Deaglio S
Blood; 2011 Dec; 118(23):6141-52. PubMed ID: 21998208
[TBL] [Abstract][Full Text] [Related]
38. Regulatory T cells participate in CD39-mediated protection from renal injury.
Wang YM; McRae JL; Robson SC; Cowan PJ; Zhang GY; Hu M; Polhill T; Wang Y; Zheng G; Wang Y; Lee VW; Unwin RJ; Harris DC; Dwyer KM; Alexander SI
Eur J Immunol; 2012 Sep; 42(9):2441-51. PubMed ID: 22684996
[TBL] [Abstract][Full Text] [Related]
39. Alteration of purinergic signaling in diabetes: Focus on vascular function.
Zhou R; Dang X; Sprague RS; Mustafa SJ; Zhou Z
J Mol Cell Cardiol; 2020 Mar; 140():1-9. PubMed ID: 32057736
[TBL] [Abstract][Full Text] [Related]
40. Adenosine and the adenosine A2A receptor agonist, CGS21680, upregulate CD39 and CD73 expression through E2F-1 and CREB in regulatory T cells isolated from septic mice.
Bao R; Shui X; Hou J; Li J; Deng X; Zhu X; Yang T
Int J Mol Med; 2016 Sep; 38(3):969-75. PubMed ID: 27430240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
